DIABETES

Question 1

Incretin mimetics (GLP1 agonist)

Answer 1

Exenatide (bydureon), liraglutiide (victoza) semiglutide (ozempic) dulaglutide (trulicity)
-cause weight loss, decrease hgba1c by 1%; increased beta cell growth, decrease glucose emptying and gluconeogenesis

Question 2

Liraglutide (victoza), semaglutide (ozempic) and dulaglutide (trulicity)

Answer 2

Have shown to decrease CV risk; good for obese patients failing meds

Question 3

DPP4 Inhibitors

Answer 3

sitagliptin (januvia), saxagliptin (onglyza has potential CHF risk), Linagliptin (tradjenta) and alogliptin (nesia) ; dPP4 inhibits glp1; good in CKD especially linagliptin

Question 4

Amalyn analogues

Answer 4

Pramlanitide (symlin) slows gastric emptying, decreases glucagon secretion, weight loss, early satiety

Question 5

SGL2 inhibitors

Answer 5

canagliflozin (invokana), dapagiflozin (farxiga), emagliflozin (jardiance) –> blocks reapsorption of glucose by the kidneys increasing glucose excretion in the urine

Question 6

Dapagiflozin (farxiga)

Answer 6

Shown to reduce HF hospitalizations and exacerbations

Question 7

Empagliflozin (jardiance) and canagliflozin (invokana)

Answer 7

Reduce incidence of ESRD and hospitalizations due to HF; decreased CV deaths